AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31874290 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing of anticoagulation reinitiation
Number of subjects: 81
Study 31874290 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived risk of stroke and SDH reaccumulation
Number of subjects: 81
Study 30230681 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous DDM granules
Number of subjects: 40
Study 30230681 — intervention group
Group type: COMPARATOR
Intervention: Bio-Oss granules
Number of subjects: 40
Study 27447483 — intervention group
Group type: EXPERIMENTAL
Intervention: Very early stepping verticalization protocol (15 sessions of 30 minutes each using a tilt table with robotic stepping device)
Number of subjects: 40
Study 27447483 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy alone
Number of subjects: 40
Study 24722495 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer Leader (PL) intervention
Number of subjects: 116
Study 24722495 — intervention group
Group type: COMPARATOR
Intervention: Community Health Worker (CHW) intervention
Number of subjects: 116
Study 24722495 — intervention group
Group type: COMPARATOR
Intervention: Both groups (PL and CHW)
Number of subjects: 116
Study 22878279 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung volume reduction surgery (LVRS)
Number of subjects: 1077
Study 22878279 — intervention group
Group type: COMPARATOR
Intervention: Medical arm
Number of subjects: 1077
Study 20978144 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 5 mg
Number of subjects: 60
Study 20978144 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 25 mg
Number of subjects: 60
Study 18855269 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/day telmisartan
Number of subjects: 30
Study 18855269 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg/day telmisartan
Number of subjects: 30
Study 16026559 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebellar stimulation ON
Number of subjects: 5
Study 12453548 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 48
Study 12453548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 12135033 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapering course of vancomycin
Number of subjects: 163
Study 12135033 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed dosing of vancomycin
Number of subjects: 163
Study 12135033 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vancomycin (> or =2 g/day)
Number of subjects: 163
Study 12135033 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose metronidazole (< or =1 g/day)
Number of subjects: 163
Study 12135033 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 163
Study 12135033 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 163
Study 9834039 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 10
Study 8122510 — intervention group
Group type: EXPERIMENTAL
Intervention: Active immunization with third party leukocytes
Number of subjects: 66
Study 8122510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 2679473 — intervention group
Group type: EXPERIMENTAL
Intervention: Hourly doses of clonidine hydrochloride followed by maintenance therapy (group 1)
Number of subjects: 64
Study 2679473 — intervention group
Group type: EXPERIMENTAL
Intervention: An initial dose of clonidine followed by hourly placebo and subsequent maintenance therapy (group 2)
Number of subjects: 64
Study 2679473 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy without prior loading (group 3)
Number of subjects: 64
Study 2679473 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (1, 2, and 3)
Number of subjects: 64
Study 766165 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyloxapol (Tacholiquin, Alevaire)
Number of subjects: 24
Study 766165 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 24
Study 766165 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyloxapol
Number of subjects: 24
Study 30924997 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D deep convolutional neural network (CNN) for breast cancer diagnosis
Number of subjects: 1537
Study 28642008 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily concurrent chemoradiotherapy (66 Gy in 33 fractions of 2 Gy over 45 days)
Number of subjects: 547
Study 28642008 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily concurrent chemoradiotherapy (45 Gy in 30 fractions of 1.5 Gy over 19 days)
Number of subjects: 547
Study 28642008 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily concurrent chemoradiotherapy
Number of subjects: 547
Study 28642008 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily concurrent chemoradiotherapy
Number of subjects: 547
Study 28642008 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 547
Study 25934525 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin (25 mg titrated up to 50 mg)
Number of subjects: 20
Study 25934525 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride (0.5 mg titrated up to 1 mg)
Number of subjects: 20
Study 24204757 — intervention group
Group type: EXPERIMENTAL
Intervention: r/LPV + RAL
Number of subjects: 210
Study 24204757 — intervention group
Group type: COMPARATOR
Intervention: r/LPV + N(t)RTI
Number of subjects: 210
Study 21742276 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 6
Study 21742276 — intervention group
Group type: COMPARATOR
Intervention: Rest (Control)
Number of subjects: 6
Study 19403270 — intervention group
Group type: EXPERIMENTAL
Intervention: Social recovery orientated cognitive behavioural therapy (SRCBT)
Number of subjects: 77
Study 19403270 — intervention group
Group type: COMPARATOR
Intervention: Case management alone (CMA)
Number of subjects: 77
Study 16368639 — intervention group
Group type: EXPERIMENTAL
Intervention: Attainable goal group
Number of subjects: 24
Study 16368639 — intervention group
Group type: COMPARATOR
Intervention: Unattainable goal group
Number of subjects: 24
Study 15486607 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline or Fluoxetine
Number of subjects: 19
Study 11110112 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg)
Number of subjects: 0
Study 11110112 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9058213 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative plasmapheresis (IP)
Number of subjects: 293
Study 9058213 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intraoperative plasmapheresis)
Number of subjects: 293
Study 8371822 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (2 dd 150 mg) for 2 weeks
Number of subjects: 30
Study 8371822 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 30
Study 31292181 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease activity‐guided tapering of biological disease-modifying antirheumatic drugs (bDMARDs)
Number of subjects: 180
Study 31292181 — intervention group
Group type: COMPARATOR
Intervention: Continuation of bDMARDs as usual care
Number of subjects: 180
Study 28267942 — intervention group
Group type: EXPERIMENTAL
Intervention: Room air cerebral tissue oxygen saturation
Number of subjects: 81
Study 25399758 — intervention group
Group type: EXPERIMENTAL
Intervention: Yellow post-it notes with a handwritten message on follow-up questionnaires
Number of subjects: 499
Study 25399758 — intervention group
Group type: COMPARATOR
Intervention: No yellow post-it notes on follow-up questionnaires (Control)
Number of subjects: 499
Study 23886347 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (n = 33)
Number of subjects: 101
Study 23886347 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet intervention (n = 35)
Number of subjects: 101
Study 23886347 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 33)
Number of subjects: 101
Study 21713327 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (60 mg loading dose, 10 mg daily maintenance dose)
Number of subjects: 201
Study 21713327 — intervention group
Group type: COMPARATOR
Intervention: High-dose clopidogrel (600 mg loading dose, 150 mg daily maintenance dose)
Number of subjects: 201
Study 19958415 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation
Number of subjects: 0
Study 19958415 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dietary magnesium intake
Number of subjects: 0
Study 17234041 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial interventions with psychopharmacology as an adjunct
Number of subjects: 33
Study 17234041 — intervention group
Group type: COMPARATOR
Intervention: Psychotropic medication with psychosocial methods as an occasional adjunct
Number of subjects: 33
Study 14760258 — intervention group
Group type: EXPERIMENTAL
Intervention: Live quadrivalent rotavirus vaccine (QRV)
Number of subjects: 439
Study 14760258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 439
Study 11596949 — intervention group
Group type: EXPERIMENTAL
Intervention: CBF-targeted management strategy
Number of subjects: 189
Study 11596949 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine administration
Number of subjects: 189
Study 11596949 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine administration (larger than median dose)
Number of subjects: 189
Study 11596949 — intervention group
Group type: EXPERIMENTAL
Intervention: History of drug abuse
Number of subjects: 189
Study 11596949 — intervention group
Group type: COMPARATOR
Intervention: ICP-targeted management strategy
Number of subjects: 189
Study 9573435 — intervention group
Group type: EXPERIMENTAL
Intervention: Age appropriate intervention (program taught in Grades 6, 7, and 8)
Number of subjects: 2483
Study 9573435 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention (program taught in Grade 7)
Number of subjects: 2483
Study 9573435 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2483
Study 8145931 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamine hydrochloride
Number of subjects: 0
Study 8145931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3050087 — intervention group
Group type: EXPERIMENTAL
Intervention: Folinic acid 20 mg/week
Number of subjects: 13
Study 3050087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 31567887 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-dose PEG (4000 mL/1.73 m PEG solution, half the dose day before and half on the day of colonoscopy)
Number of subjects: 220
Study 31567887 — intervention group
Group type: COMPARATOR
Intervention: Single-dose PEG (4000 mL/1.73 m PEG solution day before colonoscopy)
Number of subjects: 220
Study 29654502 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% BSFLM
Number of subjects: 240
Study 29654502 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% BSFLM
Number of subjects: 240
Study 29654502 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% BSFLM
Number of subjects: 240
Study 29654502 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% BSFLM
Number of subjects: 240
Study 29654502 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% BSFLM
Number of subjects: 240
Study 29654502 — intervention group
Group type: COMPARATOR
Intervention: Control (100% fishmeal)
Number of subjects: 240
Study 27484356 — intervention group
Group type: EXPERIMENTAL
Intervention: Delivery based on ductus venosus (DV) Doppler pulsatility index (PI) with safety-net criteria of very low STV on cardiotocography (CTG) and/or recurrent FHR decelerations
Number of subjects: 149
Study 27484356 — intervention group
Group type: COMPARATOR
Intervention: CTG monitoring only
Number of subjects: 149
Study 27484356 — intervention group
Group type: COMPARATOR
Intervention: CTG monitoring
Number of subjects: 149
Study 27484356 — intervention group
Group type: EXPERIMENTAL
Intervention: DV monitoring with safety-net criteria
Number of subjects: 149
Study 27484356 — intervention group
Group type: EXPERIMENTAL
Intervention: Low STV and/or recurrent FHR decelerations
Number of subjects: 149
Study 26216729 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytotoxic therapy plus concurrent and maintenance bevacizumab
Number of subjects: 1107
Study 26216729 — intervention group
Group type: COMPARATOR
Intervention: Cytotoxic therapy plus placebo
Number of subjects: 1107
Study 23040721 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholics Anonymous attendance (specifically the 'Added AA' subgroup)
Number of subjects: 0
Study 23040721 — intervention group
Group type: COMPARATOR
Intervention: Potential AA subgroup (those who would have attended AA if exposed to TSF)
Number of subjects: 0
Study 20961574 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin
Number of subjects: 104
Study 20961574 — intervention group
Group type: EXPERIMENTAL
Intervention: Enuresis alarm
Number of subjects: 104
Study 20961574 — intervention group
Group type: COMPARATOR
Intervention: Enuresis alarm (as second line treatment)
Number of subjects: 104
Study 20961574 — intervention group
Group type: COMPARATOR
Intervention: Desmopressin (as second line treatment)
Number of subjects: 104
Study 18416257 — intervention group
Group type: EXPERIMENTAL
Intervention: CeeOn diffractive multifocal IOL (n = 10)
Number of subjects: 30
Study 18416257 — intervention group
Group type: EXPERIMENTAL
Intervention: Array refractive multifocal IOL (n = 10)
Number of subjects: 30
Study 18416257 — intervention group
Group type: EXPERIMENTAL
Intervention: Mix & match group (n = 10)
Number of subjects: 30
Study 18416257 — intervention group
Group type: COMPARATOR
Intervention: Phakic controls (not specified how many)
Number of subjects: 30
Study 16894312 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (ascorbic acid 500 mg, D-alpha-tocopherol 945 IU, selenium 200 microg)
Number of subjects: 23
Study 16894312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 16894312 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation
Number of subjects: 23
Study 14680093 — intervention group
Group type: EXPERIMENTAL
Intervention: Face mask spirometry
Number of subjects: 22
Study 14680093 — intervention group
Group type: COMPARATOR
Intervention: Conventional mouthpiece
Number of subjects: 22
Study 10962676 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact endoscopy
Number of subjects: 8
Study 8977677 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacalcitol ointment (4 micrograms/g, once daily for 8 weeks)
Number of subjects: 122
Study 8977677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 1456917 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced-air warming (n = 6)
Number of subjects: 12
Study 1456917 — intervention group
Group type: COMPARATOR
Intervention: Warmed cotton blankets (n = 6)
Number of subjects: 12
Study 1456917 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (forced-air warming and warmed cotton blankets)
Number of subjects: 12
Study 6530546 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary sodium reduced from approximately 110 to 45 mEq/24 h for a period of 24 days
Number of subjects: 124
Study 31504099 — intervention group
Group type: EXPERIMENTAL
Intervention: 3'‐sialyllactose (3'SL) at 15 weeks
Number of subjects: 87
Study 31504099 — intervention group
Group type: EXPERIMENTAL
Intervention: 3'‐sialyllactosamine (3'SLN) at 15 weeks
Number of subjects: 87
Study 31504099 — intervention group
Group type: EXPERIMENTAL
Intervention: lactodifucotetraose (LDFT) at 24 weeks
Number of subjects: 87
Study 31504099 — intervention group
Group type: EXPERIMENTAL
Intervention: Model including fasting glucose, prepregnancy BMI, gestational weight gain, age, parity, smoking, and history of macrosomia
Number of subjects: 87
Study 31504099 — intervention group
Group type: EXPERIMENTAL
Intervention: Model including fasting glucose, prepregnancy BMI, gestational weight gain, age, parity, smoking, history of macrosomia, and 3'SL
Number of subjects: 87
Study 28917383 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg ixekizumab every 2 weeks for weeks 0-12, then every 4 weeks during LTE
Number of subjects: 1346
Study 26806217 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab high-yield process (DAC HYP)
Number of subjects: 0
Study 26806217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25134636 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion intervention targeting physical activity and healthy eating over a 10-week period, repeated yearly for 20 years.
Number of subjects: 0
Study 25134636 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion intervention targeting physical activity and healthy eating with an increase in health-related quality of life due to body mass index decrease.
Number of subjects: 0
Study 22544817 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Group (EG) exercise program
Number of subjects: 151
Study 22544817 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) program
Number of subjects: 151
Study 19084683 — intervention group
Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 100
Study 19084683 — intervention group
Group type: COMPARATOR
Intervention: Spinal Anesthesia (SA)
Number of subjects: 100
Study 17942835 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular stimulant use
Number of subjects: 858
Study 17942835 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased affect regulation (decreased severity of depressive symptoms)
Number of subjects: 858
Study 17942835 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased affect regulation
Number of subjects: 858
Study 15801581 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation aid
Number of subjects: 391
Study 15801581 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to make another quit attempt
Number of subjects: 391
Study 15801581 — intervention group
Group type: EXPERIMENTAL
Intervention: Interest in reduction strategy
Number of subjects: 391
Study 15801581 — intervention group
Group type: EXPERIMENTAL
Intervention: Interest in nicotine replacement therapy (NRT)
Number of subjects: 391
Study 11764874 — intervention group
Group type: EXPERIMENTAL
Intervention: TCP-coated AML femoral implant
Number of subjects: 92
Study 11764874 — intervention group
Group type: COMPARATOR
Intervention: Standard AML femoral implant (control group)
Number of subjects: 92
Study 8996038 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional therapy (specific nutrients and supplements)
Number of subjects: 0
Study 8996038 — intervention group
Group type: COMPARATOR
Intervention: Food allergies (IgE-mediated reactions)
Number of subjects: 0
Study 8504881 — intervention group
Group type: EXPERIMENTAL
Intervention: Diva supported intensified outpatient regimen (Diva group)
Number of subjects: 56
Study 8504881 — intervention group
Group type: COMPARATOR
Intervention: Intensified outpatient control (Control group A)
Number of subjects: 56
Study 8504881 — intervention group
Group type: COMPARATOR
Intervention: Conventional outpatient control (Control group B)
Number of subjects: 56
Study 3318089 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical bacillus Calmette-Guerin (BCG)
Number of subjects: 116
Study 3318089 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin hydrochloride (Adriamycin [ADR])
Number of subjects: 116
Study 3318089 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG or ADR (in cases of treatment failure)
Number of subjects: 116
Study 31836448 — intervention group
Group type: EXPERIMENTAL
Intervention: Roll (permitted to roll up sleeves)
Number of subjects: 10
Study 31836448 — intervention group
Group type: COMPARATOR
Intervention: No Roll (instructed to remain with long sleeves)
Number of subjects: 10
Study 29514803 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 695501
Number of subjects: 645
Study 29514803 — intervention group
Group type: COMPARATOR
Intervention: Humira
Number of subjects: 645
Study 29514803 — intervention group
Group type: EXPERIMENTAL
Intervention: Switched from Humira to BI 695501
Number of subjects: 645
Study 27726290 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel, Cisplatin, and 5-Fluorouracil (DCF) regimen
Number of subjects: 851
Study 27726290 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 851
Study 24239451 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical spine manipulation
Number of subjects: 10
Study 24239451 — intervention group
Group type: EXPERIMENTAL
Intervention: Various head positions
Number of subjects: 10
Study 22418809 — intervention group
Group type: EXPERIMENTAL
Intervention: CCIV/TIV
Number of subjects: 2609
Study 22418809 — intervention group
Group type: EXPERIMENTAL
Intervention: CCIV/TIV with concomitant pneumococcal vaccine (PV)
Number of subjects: 2609
Study 22418809 — intervention group
Group type: EXPERIMENTAL
Intervention: CCIV with PV
Number of subjects: 2609
Study 20973324 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice applied 5 minutes before injection
Number of subjects: 60
Study 20973324 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice applied 5 minutes after injection
Number of subjects: 60
Study 20973324 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ice application)
Number of subjects: 60
Study 18273670 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligasure
Number of subjects: 110
Study 18273670 — intervention group
Group type: COMPARATOR
Intervention: Diathermy
Number of subjects: 110
Study 16187176 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy (standard treatment for HCV)
Number of subjects: 10
Study 12537187 — intervention group
Group type: COMPARATOR
Intervention: Standard prime (SP) volume (1,602 +/- 202 mL crystalloid prime, n = 10)
Number of subjects: 20
Study 12537187 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde autologous priming (RAP) (395 +/- 150 mL)
Number of subjects: 20
Study 10768524 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral training program consisting of gesture‐production exercises (35 sessions, 50 minutes each)
Number of subjects: 13
Study 10768524 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment for aphasia
Number of subjects: 13
Study 8822675 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance System measures (leaning forward, leaning to the paretic side, maintaining symmetrical posture)
Number of subjects: 20
Study 8822675 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Independence Measure (FIM)
Number of subjects: 20